171663-13-1

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 3-BROMOBENZYLCARBAMATE is used as a building block for the synthesis of various pharmaceuticals. Its protective role in peptide synthesis allows for the creation of complex drug molecules with specific functionalities, contributing to the development of new and effective medications.
Used in Agrochemical Industry:
In the agrochemical sector, TERT-BUTYL 3-BROMOBENZYLCARBAMATE is utilized as a component in the production of agrochemicals. Its protective capabilities during synthesis processes enable the creation of compounds with targeted effects on pests or crops, enhancing the efficiency and selectivity of these products.
Used in Organic Synthesis:
TERT-BUTYL 3-BROMOBENZYLCARBAMATE is employed as a protective agent in organic synthesis. Its ability to shield specific functional groups during reactions is crucial for the successful synthesis of complex organic compounds, making it an indispensable tool in the field of organic chemistry.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 39959-54-1 3-bromobenzylamine hydrochloride 
• 10269-01-9 3-bromobenzylamine 
• 1228693-08-0 C₂₃H₂₁BrF₁₇NO₃ 
• 823-78-9 meta-bromobenzyl bromide 
• 183735-18-4 2-(3-bromobenzyl)isoindoline-1,3-dione 

Downstream Products

• 603126-93-8 2-benzenesulfonylamino-3-({5-[3-(tert-butoxycarbonylamino-methyl)-phenyl]-thiophene-2-carbonyl}-amino)-propionic acid tert-butyl ester 
• 832114-05-3 tert-butyl (3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate 
• 317358-61-5 tert-butyl (3-bromo-benzyl)-N-methylcarbamate 
• 903556-08-1 C₁₄H₁₈F₃NO₃ 
• 214956-91-9 2-amino-3'-tert-butoxycarbonylaminomethyl-5-chlorobenzophenone 
• 214957-92-3 2-amino-3'-tert-butoxycarbonylaminomethyl-5-(3-phenylpropyloxy)benzophenone 
• 214960-22-2 2-amino-3'-tert-butoxycarbonylaminomethyl-5-isobutyloxy-benzophenone 
• 398150-56-6 tert-butyl (3-bromo-benzyl)propylcarbamate 
• 170853-04-0 t-butyl N-(3-formylbenzyl)carbamate 
• 1108723-65-4 tert-butyl 3-cyclopropylbenzylcarbamate 
• 916213-93-9 tert-butyl (3-cyanobenzyl)carbamate 
• 67344-77-8 1-(3-bromophenyl)-N-methylmethanamine 
• 1221400-08-3 tert-butyl 3-neopentylbenzylcarbamate 
• 1257310-89-6 [3-(tert-butoxycarbonylaminomethyl)phenyl]carbamic acid 2-trimethylsilanylethyl ester 

Relevant academic research and scientific papers

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.

Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy

CARM1 is a protein arginine methyltransferase and acts as a transcriptional coactivator regulating multiple biological processes. Aberrant expression of CARM1 has been related to the progression of multiple types of cancers, and therefore CARM1 was consid

First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate

Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitor

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF

Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.

K-RAS MODULATORS WITH A VINYL SULFONAMIDE MOIETY

Provided herein are compounds comprising a vinyl sulfonamide moiety. Also provided herein are pharmaceutical compositions comprising such compounds, and methods of using such compounds and pharmaceutical compositions for inhibiting the post-translational

CHEMICAL COMPOUNDS

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to FormμLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be usefμL in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Arginine methyltransferase inhibitor and pharmaceutical composition and application thereof

The invention relates to an arginine methyltransferase inhibitor and a pharmaceutical composition and application thereof, in particular to a compound represented by a formula (I), a pharmaceuticallyacceptable salt, isomer, racemate, prodrug, co-crystal c

NOVEL NON-SYSTEMIC TGR5 AGONISTS

The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-sytemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.